Oxaliplatin

證據等級: L5

預測適應症: 4 個

Oxaliplatin: From Colorectal Cancer to Malignant Pleural Mesothelioma

One-Sentence Summary

Oxaliplatin is a third-generation platinum-based chemotherapy agent, historically established in colorectal cancer treatment. The TxGNN model predicts it may be effective for Malignant Pleural Mesothelioma (MPM), with 6 clinical trials (including two Phase 2 trials directly testing oxaliplatin regimens) and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Colorectal cancer (general pharmacological reference; no NZ-specific approved indication text on file)
Predicted New Indication	Malignant Pleural Mesothelioma
TxGNN Prediction Score	99.68%
Evidence Level	L2
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacological information, oxaliplatin is a third-generation DACH-platinum compound, and its efficacy in colorectal cancer has been well established; mechanistically it may also be applicable to malignant pleural mesothelioma.

Oxaliplatin acts by forming DNA inter- and intra-strand crosslinks, triggering apoptosis — a mechanism it shares with cisplatin and carboplatin. The current standard of care for MPM is a platinum-based doublet (cisplatin or carboplatin plus pemetrexed), so oxaliplatin's mechanistic profile positions it as a plausible platinum substitute, particularly for patients with renal impairment or cisplatin intolerance.

This rationale is supported by multiple completed Phase 2 single-arm studies combining oxaliplatin with gemcitabine, raltitrexed, or vinorelbine in MPM, which demonstrate biological activity consistent with the platinum-crosslinking mechanism, even though none have yet reached the scale of a confirmatory randomized trial.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00859469	Phase 2	Completed	29	Oxaliplatin (Eloxatin®) plus gemcitabine as first- or second-line chemotherapy in pleural/peritoneal mesothelioma; evaluates response rate
NCT00996385	Phase 2	Unknown	29	Velcade plus Eloxatin in previously treated MPM/peritoneal mesothelioma patients; tumor response assessed by CT every 2 cycles
NCT03210298	N/A	Unknown	1000	Multicenter international registry of Pressurized IntraPeritoneal/IntraThoracic Aerosol Chemotherapy (PIPAC/PITAC) for malignant pleural and peritoneal disease; indirect procedural evidence

Three additional trials (NCT06310473, NCT07532902, NCT05107674) were identified in the search but assessed as not directly relevant to oxaliplatin in MPM (different tumor types or unrelated investigational agents) and are omitted.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
12525529	2003	Phase II trial	J Clin Oncol	Raltitrexed + oxaliplatin combination active in 70 patients with diffuse MPM
14609447	2003	Cohort	Clinical Lung Cancer	Multicenter Phase 2 trial of gemcitabine + oxaliplatin in 25 MPM patients
19091133	2008	Cohort	J Occup Med Toxicol	Observational study of oxaliplatin ± gemcitabine in pretreated MPM patients
11989592	2001	Cohort	Tumori	Pilot study of oxaliplatin + raltitrexed in inoperable MPM
15639727	2005	Phase II trial	Lung Cancer	Vinorelbine + oxaliplatin as first-line therapy in MPM
15893013	2005	Phase II trial	Lung Cancer	Raltitrexed-oxaliplatin inactive as second-line treatment in 14 MPM patients
10930799	2000	Institutional review	Eur J Cancer	Institut Gustave Roussy 9-year experience (163 patients) with chemo/chemo-immunotherapy in mesothelioma
26526504	2015	Review	Cancer Treat Rev	Reviews therapeutic options in MPM, positions platinum/pemetrexed as standard first-line
31455014	2019	Review	Int J Mol Sci	Evaluates oxaliplatin, cisplatin, and pemetrexed effects on immune checkpoint expression in MPM
10936465	2000	Review	Crit Rev Oncol Hematol	Overview of oxaliplatin clinical activity across tumor types

New Zealand Market Information

Oxaliplatin currently has no product authorizations on file in New Zealand (Medsafe market status: Not Marketed; 0 authorizations recorded).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (third-generation platinum compound, DACH-platinum)
Myelosuppression Risk	No incidence data available in this evidence pack — please refer to the package insert warnings and precautions
Emetogenicity Classification	Moderate to high (standard classification for platinum-based agents)
Monitoring Items	CBC with differential, renal function, liver function, peripheral neuropathy assessment
Handling Protection	Cytotoxic drug handling precautions required per standard hazardous drug protocols

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: While the mechanistic rationale and multiple completed Phase 2 studies support biological activity of oxaliplatin-based regimens in MPM (Evidence Level L2), the TFDA/Medsafe package insert data (warnings, contraindications, DDI) is entirely unavailable — a Blocking-severity gap that prevents even the initial safety assessment (S1). The drug is also currently not marketed in New Zealand.

To proceed, the following is needed:

Package insert / regulatory safety data (warnings, contraindications, drug interactions) from Medsafe or the manufacturer
Confirmed mechanism of action documentation (DrugBank or primary literature)
Assessment of the New Zealand market entry pathway given the current "Not Marketed" status
Maturation of trial evidence — several key trials remain small (N=29) or have Unknown/incomplete status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.